S&P 500   4,283.64 (-0.10%)
DOW   33,401.65 (-0.32%)
QQQ   360.06 (+0.50%)
AAPL   173.08 (+1.09%)
MSFT   317.77 (+0.64%)
META   305.09 (+1.63%)
GOOGL   132.94 (+1.59%)
AMZN   128.54 (+1.12%)
TSLA   246.32 (-1.56%)
NVDA   444.68 (+2.23%)
NIO   8.88 (-1.77%)
BABA   86.40 (-0.39%)
AMD   103.03 (+0.20%)
T   14.95 (-0.47%)
F   12.34 (-0.64%)
MU   68.85 (+1.21%)
CGC   0.78 (-0.37%)
GE   111.03 (+0.43%)
DIS   80.93 (-0.15%)
AMC   8.18 (+2.38%)
PFE   33.13 (-0.12%)
PYPL   58.78 (+0.55%)
NFLX   380.46 (+0.76%)
S&P 500   4,283.64 (-0.10%)
DOW   33,401.65 (-0.32%)
QQQ   360.06 (+0.50%)
AAPL   173.08 (+1.09%)
MSFT   317.77 (+0.64%)
META   305.09 (+1.63%)
GOOGL   132.94 (+1.59%)
AMZN   128.54 (+1.12%)
TSLA   246.32 (-1.56%)
NVDA   444.68 (+2.23%)
NIO   8.88 (-1.77%)
BABA   86.40 (-0.39%)
AMD   103.03 (+0.20%)
T   14.95 (-0.47%)
F   12.34 (-0.64%)
MU   68.85 (+1.21%)
CGC   0.78 (-0.37%)
GE   111.03 (+0.43%)
DIS   80.93 (-0.15%)
AMC   8.18 (+2.38%)
PFE   33.13 (-0.12%)
PYPL   58.78 (+0.55%)
NFLX   380.46 (+0.76%)
S&P 500   4,283.64 (-0.10%)
DOW   33,401.65 (-0.32%)
QQQ   360.06 (+0.50%)
AAPL   173.08 (+1.09%)
MSFT   317.77 (+0.64%)
META   305.09 (+1.63%)
GOOGL   132.94 (+1.59%)
AMZN   128.54 (+1.12%)
TSLA   246.32 (-1.56%)
NVDA   444.68 (+2.23%)
NIO   8.88 (-1.77%)
BABA   86.40 (-0.39%)
AMD   103.03 (+0.20%)
T   14.95 (-0.47%)
F   12.34 (-0.64%)
MU   68.85 (+1.21%)
CGC   0.78 (-0.37%)
GE   111.03 (+0.43%)
DIS   80.93 (-0.15%)
AMC   8.18 (+2.38%)
PFE   33.13 (-0.12%)
PYPL   58.78 (+0.55%)
NFLX   380.46 (+0.76%)
S&P 500   4,283.64 (-0.10%)
DOW   33,401.65 (-0.32%)
QQQ   360.06 (+0.50%)
AAPL   173.08 (+1.09%)
MSFT   317.77 (+0.64%)
META   305.09 (+1.63%)
GOOGL   132.94 (+1.59%)
AMZN   128.54 (+1.12%)
TSLA   246.32 (-1.56%)
NVDA   444.68 (+2.23%)
NIO   8.88 (-1.77%)
BABA   86.40 (-0.39%)
AMD   103.03 (+0.20%)
T   14.95 (-0.47%)
F   12.34 (-0.64%)
MU   68.85 (+1.21%)
CGC   0.78 (-0.37%)
GE   111.03 (+0.43%)
DIS   80.93 (-0.15%)
AMC   8.18 (+2.38%)
PFE   33.13 (-0.12%)
PYPL   58.78 (+0.55%)
NFLX   380.46 (+0.76%)
NASDAQ:NERV

Minerva Neurosciences (NERV) Stock Forecast, Price & News

$6.97
+0.07 (+1.01%)
(As of 09:30 AM ET)
Compare
Today's Range
$6.97
$6.97
50-Day Range
$6.90
$10.52
52-Week Range
$1.26
$14.70
Volume
620 shs
Average Volume
401,982 shs
Market Capitalization
$48.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Minerva Neurosciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
59.4% Upside
$11.00 Price Target
Short Interest
Healthy
1.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.89
Upright™ Environmental Score
News Sentiment
0.63mentions of Minerva Neurosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.94) to ($3.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

315th out of 969 stocks

Pharmaceutical Preparations Industry

129th out of 454 stocks


NERV stock logo

About Minerva Neurosciences (NASDAQ:NERV) Stock

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

NERV Price History

NERV Stock News Headlines

Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
Insomnia Medication Market Forecast to 2030
See More Headlines
Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

NERV Company Calendar

Last Earnings
8/01/2023
Today
10/02/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NERV
Fax
N/A
Employees
9
Year Founded
2007

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+59.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-32,110,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$41.18 million
Book Value
($3.75) per share

Miscellaneous

Free Float
6,545,000
Market Cap
$48.23 million
Optionable
Optionable
Beta
0.25

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Remy Luthringer Ph.D. (Age 62)
    Exec. Chairman & CEO
    Comp: $853.58k
  • Mr. Geoffrey Robin Race F.C.M.A. (Age 62)
    FCMA, M.B.A., MBA, Pres
    Comp: $628.46k
  • Mr. Frederick W. Ahlholm CPA (Age 57)
    CPA, Sr. VP, CFO & Sec.
    Comp: $567.49k
  • Mr. Joseph Reilly (Age 48)
    Sr. VP & COO
  • Mr. William B. Boni (Age 71)
    VP of Investor Relations & Corp. Communications
  • Prof. Michael Davidson M.D. (Age 73)
    Chief Medical Officer
  • Dr. Ramana Kuchibhatla Ph.D.
    Sr. VP and Head of R&D













NERV Stock - Frequently Asked Questions

Should I buy or sell Minerva Neurosciences stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NERV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NERV, but not buy additional shares or sell existing shares.
View NERV analyst ratings
or view top-rated stocks.

What is Minerva Neurosciences' stock price forecast for 2023?

2 equities research analysts have issued 12 month price targets for Minerva Neurosciences' shares. Their NERV share price forecasts range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 59.4% from the stock's current price.
View analysts price targets for NERV
or view top-rated stocks among Wall Street analysts.

How have NERV shares performed in 2023?

Minerva Neurosciences' stock was trading at $1.59 at the beginning of the year. Since then, NERV stock has increased by 334.0% and is now trading at $6.90.
View the best growth stocks for 2023 here
.

When is Minerva Neurosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our NERV earnings forecast
.

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) issued its quarterly earnings results on Tuesday, August, 1st. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.68.

When did Minerva Neurosciences' stock split?

Minerva Neurosciences shares reverse split on the morning of Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

How do I buy shares of Minerva Neurosciences?

Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $6.90.

How much money does Minerva Neurosciences make?

Minerva Neurosciences (NASDAQ:NERV) has a market capitalization of $48.23 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $-32,110,000.00 in net income (profit) each year or ($4.98) on an earnings per share basis.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The official website for the company is www.minervaneurosciences.com. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at wboni@minervaneurosciences.com.

This page (NASDAQ:NERV) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -